# Hepatitis Delta virus treatment developments

> Live situation record from CLSTR: https://clstr.news/situations/hepatitis-delta-virus-treatment-developments
> Updated: 2026-10-26T10:20:00.000Z. Sources: 6. Developments: 2.

Recent developments in the management of chronic hepatitis delta virus (HDV) highlight a transition from a lack of approved therapies to an accelerating landscape of medical advancements. 

Clinical research has shown progress with investigational treatments, such as the monoclonal antibody brelovitug. In the Phase 3 AZURE-1 trial, patients receiving brelovitug achieved combined virologic response and alanine aminotransferase (ALT) normalization at rates of 56% and 45% depending on dosage, compared to 0% in the delayed treatment group. This therapy aims to control the virus and liver inflammation to prevent progression to cirrhosis, liver failure, or liver cancer.

At the fifth International Delta Cure Meeting in Milan, experts noted that while HDV remains the most aggressive form of chronic viral hepatitis, the availability of treatments is increasing. Bulevirtide has emerged as the first specific treatment available in clinical practice, demonstrating virological and biochemical responses with a strong safety profile. Several other therapeutic strategies are currently in advanced stages of development.

## Claims

- The fifth International Delta Cure Meeting was held in Milan. (corroborated by 3 sources)
- Hepatitis Delta is considered the most aggressive form of chronic viral hepatitis. (corroborated by 3 sources)
- Bulevirtide is currently the only specific treatment available in clinical practice for chronic Hepatitis Delta. (corroborated by 3 sources)
- There are numerous new therapeutic strategies for HDV in advanced stages of development. (corroborated by 3 sources)
- In Italy, the number of patients with active HDV infection is estimated to be in the thousands. (corroborated by 3 sources)
- Bulevirtide has shown a good safety profile in patients with advanced liver disease. (single source)

## Timeline

### 2026-10-26: Hepatitis Delta treatment landscape shifts at International Delta Cure Meeting

Experts at the International Delta Cure Meeting in Milan announced new advancements for Hepatitis Delta, including the availability of bulevirtide and several new therapies in advanced development.

6 sources. https://clstr.news/cluster/hepatitis-delta-treatment-landscape-shifts-at-international-delta-cure-meeting

### 2026-09-28: Mirum Pharmaceuticals reports positive Phase 3 results for hepatitis delta treatment

Mirum Pharmaceuticals' Phase 3 AZURE-1 trial for brelovitug met its primary endpoint, showing significant virologic response and ALT normalization in patients with chronic hepatitis delta virus.

6 sources. https://clstr.news/cluster/mirum-pharmaceuticals-reports-positive-phase-3-results-for-hepatitis-delta-treatment

---
Cite as: Hepatitis Delta virus treatment developments. CLSTR, https://clstr.news/situations/hepatitis-delta-virus-treatment-developments